.png){kind=icon}
.png){kind=icon}
Return
Comparative safety of lipid-lowering drugs alone or in combination: insights from a systematic review and network meta-analysis
.png){kind=icon}
OA
AI
S
F
E
M
DOI：10.1016/j.numecd.2026.104851.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• Network meta-analysis of 153 RCTs compares safety of major lipid-lowering therapies. • PCSK9 inhibitors show lower risks of CK elevation, diabetes, and liver dysfunction. • Bempedoic acid ranks lowest for myalgia risk, supporting use in statin intolerance. • No significant differences found in overall muscle events or cognitive disorders. • Safety profiles can guide personalized LLT selection in patients at higher risk.
Keywords:
Adverse events
Lipid-lowering therapies
Safety
Network meta-analysis
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
N
IF:
0
Papers:
307
Citations:
0
Organization
Cited Papers